• LAST PRICE
    28.5001
  • TODAY'S CHANGE (%)
    Trending Down-0.1599 (-0.5579%)
  • Bid / Lots
    11.4000/ 2
  • Ask / Lots
    45.6000/ 2
  • Open / Previous Close
    28.6600 / 28.6600
  • Day Range
    Low 28.3600
    High 28.6600
  • 52 Week Range
    Low 17.0800
    High 33.0700
  • Volume
    5,054
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 28.66
TimeVolumePRTC
09:32 ET10028.66
09:50 ET100028.65
09:52 ET43828.65
09:54 ET47828.65
10:01 ET20028.65
10:03 ET10028.65
10:17 ET100028.36
02:56 ET122528.5001
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesPRTC
PureTech Health PLC
767.6M
-16.3x
---
United StatesAPLT
Applied Therapeutics Inc
725.3M
-4.8x
---
United StatesPRAX
Praxis Precision Medicines Inc
783.7M
-2.6x
---
United StatesCGEM
Cullinan Oncology Inc
763.6M
-4.6x
---
United StatesHLVX
Hillevax Inc
776.3M
-5.5x
---
United StatesNKTX
Nkarta Inc
778.1M
-4.5x
---
As of 2024-03-28

Company Information

PureTech Health plc is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company's R&D engine has developed 27 therapeutics and therapeutic candidates, including two (Plenity and EndeavorRx) that have received both United States (US) Food and Drug Administration (FDA) clearance and European marketing authorization. The Company's pipeline includes LYT-100, LYT-200, LYT-300, LYT-310 and LYT-503/IMB-150. LYT-100 (deupirfenidone) is being advanced for the potential treatment of conditions involving inflammation and fibrosis. It is developing LYT-200 for the treatment of metastatic/locally advanced solid tumors that have poor survival rates, including urothelial and head and neck cancers. LYT-300 is an oral prodrug of allopregnanolone, which is being advanced for the potential treatment of anxiety disorders and postpartum depression.

Contact Information

Headquarters
6 Tide Street, Suite 400BOSTON, MA, United States 02210
Phone
617-482-2333
Fax
617-482-3337

Executives

Interim Chairman of the Board, Senior Independent Director
Raju Kucherlapati
President, Chief Financial Officer, Chief Business Officer, Chief Operating Officer, Director
Bharatt Chowrira
Chief Executive Officer, Founder, Director
Daphne Zohar
Co-Founder, Non-Executive Director
Robert Langer
Chief Innovation and Strategy Officer
Eric Elenko

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$767.6M
Revenue (TTM)
$15.6M
Shares Outstanding
27.0M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.22
EPS
$-1.75
Book Value
$19.46
P/E Ratio
-16.3x
Price/Sales (TTM)
49.1
Price/Cash Flow (TTM)
---
Operating Margin
-965.08%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.